NeuroMetrix Showcases Quell® Technology at the New York Podiatric Clinical Conference

The Only FDA Cleared Wearable Device for 24/7 Chronic Pain Relief Without a Prescription

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology will be exhibited at NY16 - Podiatric Clinical Conference and Exhibition sponsored by the NYS Podiatric Medical Association. NY16 is New York's premier event for podiatrists and health-care professionals with attendance expected to include nearly 3,000 DPMs, MDs, Podiatric Assistants, Students, and Residents. The conference includes scientific lectures, panel discussions and workshops presented by the top names in the podiatric field. It will be held on January 22 - 24, 2016 at the New York Marriott Marquis, 1535 Broadway, in New York City.

"The theme of the NY16 Meeting is The Path to Progress which aligns with our breakthrough technology in Quell," says Frank McGillin, Senior Vice President and General Manager, Consumer. "Quell is designed to address a variety of chronic pain conditions that podiatrists encounter every day. With over 50% of patients seen by podiatrists suffering from chronic pain and many not getting adequate relief, Quell can make a real difference in the quality of medical care provided by podiatrists."

About Quell
Quell utilizes NeuroMetrix's patented neurostimulation technology to provide widespread relief from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell includes a smartphone app that tracks and personalizes their pain therapy. It is available for purchase at QuellRelief.com, selected retailers and healthcare professionals.

About NeuroMetrix
NeuroMetrix is an innovative healthcare company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160121006377/en/

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media